Morgan Lee Lekstrom Purchases 50,000 Shares of Biosig Technologies (NASDAQ:STEX) Stock

Biosig Technologies, Inc. (NASDAQ:STEX) Chairman Morgan Lee Lekstrom purchased 50,000 shares of the stock in a transaction that occurred on Friday, June 12th. The stock was purchased at an average cost of $0.99 per share, with a total value of $49,500.00. Following the purchase, the chairman owned 359,500 shares in the company, valued at $355,905. This represents a 16.16% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Morgan Lee Lekstrom also recently made the following trade(s):

• On Thursday, May 28th, Morgan Lee Lekstrom acquired 34,000 shares of Biosig Technologies stock. The stock was purchased at an average price of $1.47 per share, for a total transaction of $49,980.00.
• On Thursday, May 21st, Morgan Lee Lekstrom acquired 147,000 shares of Biosig Technologies stock. The shares were acquired at an average cost of $1.04 per share, for a total transaction of $152,880.00.
• On Tuesday, April 14th, Morgan Lee Lekstrom sold 12,759 shares of Biosig Technologies stock. The shares were sold at an average price of $1.07, for a total transaction of $13,652.13.

Biosig Technologies Price Performance

STEX stock opened at $0.99 on Wednesday. The business has a 50 day simple moving average of $1.07. Biosig Technologies, Inc. has a 12 month low of $0.70 and a 12 month high of $14.11. The company has a market capitalization of $179.62 million, a P/E ratio of -0.10 and a beta of 1.85.

Biosig Technologies (NASDAQ:STEX) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.27) earnings per share for the quarter.

Analyst Upgrades and Downgrades

STEX has been the subject of several recent analyst reports. Needham & Company LLC decreased their price target on Biosig Technologies from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, May 21st. Weiss Ratings raised Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. Finally, Wall Street Zen lowered Biosig Technologies from a “hold” rating to a “strong sell” rating in a report on Sunday, April 5th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Biosig Technologies currently has a consensus rating of “Hold” and an average target price of $8.00.

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.